Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Announcement of Issuance of New Shares Through an International Offering
Notice Regarding the Subcommittee Review Results on Partial Change Approval for AKUUGO(R)
Notice Regarding Inclusion of AKUUGO(R) Suspension for intracranial Implantation on the Committee Agenda
Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 2026
Revision of Consolidated Earnings Forecast for the Fiscal Year Ending January 2026
Notice Concerning Recording of Non-operating Expenses and Deferred Income Taxes
Consolidated Financial Results for the Six Months Ended July 31, 2025 [Japanese GAAP]
SanBio, Net Income Forecast for the Fiscal Year Loss Widened in Downward Revision
Notice on Conclusion of Committed Credit Line Agreement with MUFG Bank, Ltd.
Notice Regarding Revision of Expected Approval Timing for Partial Changes to AKUUGO(R)Suspension for Intracranial Implantation
Notice Concerning Recording of Non-operating Expenses, and Deferred Income Taxes
SanBio, Feb-Apr (1Q) Net Income Loss Widens
Consolidated Financial Results for the Three Months Ended April 30, 2025 [Japanese GAAP]
Notice of Completion of Application for Partial Change Approval of AKUUGO(R) Suspension for Intracranial Implantation
Notice on Conclusion of Committed Credit Line Agreement with Mizuho Bank, Ltd.
[Delayed] Keita Mori, Representative Director and President of SanBio, Appointed Chairman of Samurai Biotech Association
The Results of the Third Commercial Production Run of AKUUGO(R)
The Yield Results of the Third Commercial Production Run for AKUUGO(R) Suspension for Intracranial Implantation
Presentation for Financial Results for the Fiscal Year Ending January 31, 2025
Notice Concerning Recording of Non-operating Income, Non-operating Expenses, Extraordinary Gains, and Deferred Income Taxes